| SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes. | SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes.
Wang Y, Ji N, Wang J, Cao J, Li D, Zhang Y, Zhang L., Free PMC Article | 01/8/2022 |
| Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies. | Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies.
Dai C, Webster KA, Bhatt A, Tian H, Su G, Li W., Free PMC Article | 07/3/2021 |
| SCG3 may be involved in PQinduced astrocyte activation via regulation of the expression and selective recruitment of cellular factors, thus suggesting that SCG3 may represent an indicator of astrocyte activation. | Secretogranin III may be an indicator of paraquat-induced astrocyte activation and affects the recruitment of BDNF during this process.
Zhan X, Li F, Chu Q, Pang H. | 03/2/2019 |
| This review summarizes our current knowledge of Scg3 as a regulatory protein of secretory granules, highlights its new role as a highly disease-selective angiogenic factor, and envisions Scg3 inhibitors as "selective angiogenesis blockers" for targeted therapy of diabetic retinopathy. [review] | Secretogranin III: a diabetic retinopathy-selective angiogenic factor.
Li W, Webster KA, LeBlanc ME, Tian H., Free PMC Article | 10/27/2018 |
| results suggested an association between the fucosylated glycoform of short-form SgIII and Small Cell Lung Carcinoma | Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma.
Togayachi A, Iwaki J, Kaji H, Matsuzaki H, Kuno A, Hirao Y, Nomura M, Noguchi M, Ikehara Y, Narimatsu H. | 08/18/2018 |
| HBXIP facilitates the proliferation of hepatoma cells by up-regulating SCG3 via E2F1 and miR-509-3p modulation. | The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells.
Wang Y, Cui M, Cai X, Sun B, Liu F, Zhang X, Ye L. | 10/11/2014 |
| SCG3 is essential in the process and targeting of neuropeptides and neurotrophins, its participation in the pathological progression of Alzheimer's disease may be suggested | Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid β-associated neural degeneration in Alzheimer's disease.
Plá V, Paco S, Ghezali G, Ciria V, Pozas E, Ferrer I, Aguado F., Free PMC Article | 11/2/2013 |
| SCG3 may be involved in apoptosis signal transduction as a caspase substrate.It may be a pivotal component of the neuroendocrine pathway & play an important role in neuronal communication & neurotransmitter release. | Dysregulated expression of secretogranin III is involved in neurotoxin-induced dopaminergic neuron apoptosis.
Li F, Tian X, Zhou Y, Zhu L, Wang B, Ding M, Pang H. | 04/13/2013 |
| Our data suggest that genetic variations in the FTO, SCG3 and MTMR9 genes independently influence the risk of metabolic syndrome. | Association of variations in the FTO, SCG3 and MTMR9 genes with metabolic syndrome in a Japanese population.
Hotta K, Kitamoto T, Kitamoto A, Mizusawa S, Matsuo T, Nakata Y, Kamohara S, Miyatake N, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Yoneda M, Nakajima A, Funahashi T, Miyazaki S, Tokunaga K, Masuzaki H, Ueno T, Hamaguchi K, Tanaka K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Matsuzawa Y, Nakao K, Sekine A. | 03/10/2012 |
| This short review deals with investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III. | Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.
Portela-Gomes GM, Grimelius L, Stridsberg M. | 04/16/2011 |
| SgIII was expressed in 41 of 47 neuroendocrine tumours. The expression of SgIII agreed well with that of CgA, CgB and SgII, with exceptions of phaeochromocytomas and parathyroid adenomas. | Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II.
Portela-Gomes GM, Grimelius L, Stridsberg M. | 04/16/2011 |
| these data suggest that SgIII, DMT-1 and HNP-1 are implicated in cell-mediated LDL oxidation. | LDL oxidation by THP-1 monocytes: implication of HNP-1, SgIII and DMT-1.
He C, Huang R, Du F, Zheng F, Wei L, Wu J. | 01/21/2010 |
| Secretogranins III assays failed to detect increased concentrations in any of the patients with neuroendocrine tumours. | Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours.
Stridsberg M, Eriksson B, Janson ET. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Functional single-nucleotide polymorphisms in the secretogranin III (SCG3) gene that form secretory granules with appetite-related neuropeptides are associated with obesity.
Tanabe A, Yanagiya T, Iida A, Saito S, Sekine A, Takahashi A, Nakamura T, Tsunoda T, Kamohara S, Nakata Y, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Funahashi T, Miyazaki S, Tokunaga K, Hamaguchi K, Shimada T, Tanaka K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Matsuzawa Y, Kamatani N, Nakamura Y, Hotta K, Tanabe A, Yanagiya T, Iida A, Saito S, Sekine A, Takahashi A, Nakamura T, Tsunoda T, Kamohara S, Nakata Y, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Funahashi T, Miyazaki S, Tokunaga K, Hamaguchi K, Shimada T, Tanaka K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Matsuzawa Y, Kamatani N, Nakamura Y, Hotta K. | 03/13/2008 |
| Genetic variations in the SCG3 gene may influence the risk of obesity through possible regulation of hypothalamic neuropeptide secretion. | Functional single-nucleotide polymorphisms in the secretogranin III (SCG3) gene that form secretory granules with appetite-related neuropeptides are associated with obesity.
Tanabe A, Yanagiya T, Iida A, Saito S, Sekine A, Takahashi A, Nakamura T, Tsunoda T, Kamohara S, Nakata Y, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Funahashi T, Miyazaki S, Tokunaga K, Hamaguchi K, Shimada T, Tanaka K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Matsuzawa Y, Kamatani N, Nakamura Y, Hotta K, Tanabe A, Yanagiya T, Iida A, Saito S, Sekine A, Takahashi A, Nakamura T, Tsunoda T, Kamohara S, Nakata Y, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Funahashi T, Miyazaki S, Tokunaga K, Hamaguchi K, Shimada T, Tanaka K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Sakata T, Matsuzawa Y, Kamatani N, Nakamura Y, Hotta K. | 01/21/2010 |